Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study

HIGHLIGHTS

• who: Kadir Eser from the than half were excluded from the studyBased on previous endocrine time response, those with endocrine sensitivity (if relapsed at least , months after completion of adjuvant endocrine therapy or de novo metastatic breast cancer) or those who are endocrine resistant (relapse while receiving adjuvant therapy or recurrence within , months of discontinuation of adjuvant endocrine therapy and progression within the , months after initiating aromatase inhibitor in palliative therapy) [23]. According to the insurance system in our country, it is obligatory to use CDK inhibitor with letrozole in endocrine sensitive patients and with fulvestrant in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.